Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $178.54 billion. The enterprise value is $191.68 billion.
| Market Cap | 178.54B |
| Enterprise Value | 191.68B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, before market open.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Aug 17, 2026 |
Share Statistics
Novo Nordisk has 4.41 billion shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.41B |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 28.03% |
| Float | 3.16B |
Valuation Ratios
The trailing PE ratio is 10.65 and the forward PE ratio is 12.08.
| PE Ratio | 10.65 |
| Forward PE | 12.08 |
| PS Ratio | 3.52 |
| Forward PS | 3.80 |
| PB Ratio | 5.39 |
| P/TBV Ratio | 11.08 |
| P/FCF Ratio | 16.68 |
| P/OCF Ratio | 9.39 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.95, with an EV/FCF ratio of 17.90.
| EV / Earnings | 11.15 |
| EV / Sales | 3.78 |
| EV / EBITDA | 6.95 |
| EV / EBIT | 7.45 |
| EV / FCF | 17.90 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of 0.62.
| Current Ratio | 0.84 |
| Quick Ratio | 0.63 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | 1.91 |
| Interest Coverage | 65.67 |
Financial Efficiency
Return on equity (ROE) is 58.38% and return on invested capital (ROIC) is 42.60%.
| Return on Equity (ROE) | 58.38% |
| Return on Assets (ROA) | 19.05% |
| Return on Invested Capital (ROIC) | 42.60% |
| Return on Capital Employed (ROCE) | 48.45% |
| Weighted Average Cost of Capital (WACC) | 5.78% |
| Revenue Per Employee | $760,120 |
| Profits Per Employee | $257,839 |
| Employee Count | 66,700 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.13 |
Taxes
In the past 12 months, Novo Nordisk has paid $4.78 billion in taxes.
| Income Tax | 4.78B |
| Effective Tax Rate | 21.77% |
Stock Price Statistics
The stock price has decreased by -10.90% in the last 52 weeks. The beta is 0.37, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -10.90% |
| 50-Day Moving Average | 40.41 |
| 200-Day Moving Average | 43.48 |
| Relative Strength Index (RSI) | 53.93 |
| Average Volume (20 Days) | 11,020,046 |
Short Selling Information
The latest short interest is 37.44 million, so 1.18% of the outstanding shares have been sold short.
| Short Interest | 37.44M |
| Short Previous Month | 26.34M |
| Short % of Shares Out | 1.18% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.52 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $50.70 billion and earned $17.20 billion in profits. Earnings per share was $3.82.
| Revenue | 50.70B |
| Gross Profit | 42.25B |
| Operating Income | 25.74B |
| Pretax Income | 21.98B |
| Net Income | 17.20B |
| EBITDA | 27.59B |
| EBIT | 25.74B |
| Earnings Per Share (EPS) | $3.82 |
Balance Sheet
The company has $7.04 billion in cash and $20.43 billion in debt, with a net cash position of -$13.39 billion or -$3.04 per share.
| Cash & Cash Equivalents | 7.04B |
| Total Debt | 20.43B |
| Net Cash | -13.39B |
| Net Cash Per Share | -$3.04 |
| Equity (Book Value) | 33.10B |
| Book Value Per Share | 7.51 |
| Working Capital | -5.88B |
Cash Flow
In the last 12 months, operating cash flow was $19.02 billion and capital expenditures -$8.31 billion, giving a free cash flow of $10.71 billion.
| Operating Cash Flow | 19.02B |
| Capital Expenditures | -8.31B |
| Depreciation & Amortization | 1.81B |
| Net Borrowing | 4.64B |
| Free Cash Flow | 10.71B |
| FCF Per Share | $2.43 |
Margins
Gross margin is 83.33%, with operating and profit margins of 50.78% and 33.92%.
| Gross Margin | 83.33% |
| Operating Margin | 50.78% |
| Pretax Margin | 43.36% |
| Profit Margin | 33.92% |
| EBITDA Margin | 54.41% |
| EBIT Margin | 50.78% |
| FCF Margin | 21.48% |
Dividends & Yields
This stock pays an annual dividend of $1.28, which amounts to a dividend yield of 3.15%.
| Dividend Per Share | $1.28 |
| Dividend Yield | 3.15% |
| Dividend Growth (YoY) | 4.13% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 33.61% |
| FCF Payout Ratio | 52.82% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 3.35% |
| Earnings Yield | 9.39% |
| FCF Yield | 6.00% |
Analyst Forecast
The average price target for Novo Nordisk is $46.05, which is 13.15% higher than the current price. The consensus rating is "Hold".
| Price Target | $46.05 |
| Price Target Difference | 13.15% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 2.22% |
| EPS Growth Forecast (3Y) | 1.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 4.04 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.04 |
| Piotroski F-Score | 6 |